Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092273103> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2092273103 abstract "Sunitinib is a novel, multi-targeted receptor tyrosine kinase inhibitor, which has demonstrated evidence of improved survival when compared to interferon (IFN)-alpha in patients with metastatic renal cell carcinoma (RCC). Recently published National Institute for Health and Clinical Excellence guidance recommends sunitinib as a first-line treatment option for patients with advanced and/or metastatic RCC. We assessed the efficacy and toxicity of sunitinib in an unselected group of patients with metastatic RCC, and compared outcomes in clinical practice with published clinical trial results. Between June 2006 and March 2008, 56 patients with metastatic RCC gave informed consent for commencement of sunitinib treatment at our institution. Median age was 61 years (range: 33-78); 68% had clear-cell histology; 86% had undergone prior nephrectomy; and 50% had progressed on IFN-alpha prior to commencement of sunitinib. Sunitinib was administered orally at a dose of 50 mg once daily, in 6-week cycles consisting of 4 weeks of treatment followed by a 2-week break. All patients were evaluable for toxicity, and 49 for response. The mean dose of sunitinib was 38.15 mg/cycle (range: 25-50); and 402 cycles of sunitinib were delivered. Partial response and stable disease were observed in 41 and 37% of patients, respectively. Median progression-free survival and overall survival were 12.2 and 18.2 months, respectively. The most common adverse events (all grades) were mucositis (79%) and fatigue (75%). Grade 3/4 neutropenia was observed in 13%, and treatment-related hypothyroidism in 20%, of patients. Dose-reduction was necessary in 75% of patients, and 32% needed hospital admission for treatment-related toxicities. The results from this study confirm the efficacy of sunitinib in the first- and second-line treatment of an unselected group of patients with metastatic RCC. Compared to published data, there was a higher incidence of treatment-related toxicities and a greater necessity for dose-reductions. Despite the increase in toxicity, these results are encouraging and imply that the clinical trial results seen with sunitinib can be translated into routine clinical practice." @default.
- W2092273103 created "2016-06-24" @default.
- W2092273103 creator A5002598093 @default.
- W2092273103 creator A5006115145 @default.
- W2092273103 creator A5009739733 @default.
- W2092273103 creator A5022378006 @default.
- W2092273103 creator A5062301441 @default.
- W2092273103 creator A5091199848 @default.
- W2092273103 date "2010-06-25" @default.
- W2092273103 modified "2023-10-01" @default.
- W2092273103 title "Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience" @default.
- W2092273103 doi "https://doi.org/10.3892/or_00000886" @default.
- W2092273103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20596640" @default.
- W2092273103 hasPublicationYear "2010" @default.
- W2092273103 type Work @default.
- W2092273103 sameAs 2092273103 @default.
- W2092273103 citedByCount "15" @default.
- W2092273103 countsByYear W20922731032012 @default.
- W2092273103 countsByYear W20922731032013 @default.
- W2092273103 countsByYear W20922731032014 @default.
- W2092273103 countsByYear W20922731032015 @default.
- W2092273103 countsByYear W20922731032016 @default.
- W2092273103 countsByYear W20922731032017 @default.
- W2092273103 countsByYear W20922731032021 @default.
- W2092273103 crossrefType "journal-article" @default.
- W2092273103 hasAuthorship W2092273103A5002598093 @default.
- W2092273103 hasAuthorship W2092273103A5006115145 @default.
- W2092273103 hasAuthorship W2092273103A5009739733 @default.
- W2092273103 hasAuthorship W2092273103A5022378006 @default.
- W2092273103 hasAuthorship W2092273103A5062301441 @default.
- W2092273103 hasAuthorship W2092273103A5091199848 @default.
- W2092273103 hasBestOaLocation W20922731031 @default.
- W2092273103 hasConcept C121608353 @default.
- W2092273103 hasConcept C126322002 @default.
- W2092273103 hasConcept C141071460 @default.
- W2092273103 hasConcept C143998085 @default.
- W2092273103 hasConcept C197934379 @default.
- W2092273103 hasConcept C2777063308 @default.
- W2092273103 hasConcept C2777472916 @default.
- W2092273103 hasConcept C2778496288 @default.
- W2092273103 hasConcept C2778820342 @default.
- W2092273103 hasConcept C2779490328 @default.
- W2092273103 hasConcept C2780091579 @default.
- W2092273103 hasConcept C2780227381 @default.
- W2092273103 hasConcept C2781068499 @default.
- W2092273103 hasConcept C29730261 @default.
- W2092273103 hasConcept C71924100 @default.
- W2092273103 hasConcept C90924648 @default.
- W2092273103 hasConceptScore W2092273103C121608353 @default.
- W2092273103 hasConceptScore W2092273103C126322002 @default.
- W2092273103 hasConceptScore W2092273103C141071460 @default.
- W2092273103 hasConceptScore W2092273103C143998085 @default.
- W2092273103 hasConceptScore W2092273103C197934379 @default.
- W2092273103 hasConceptScore W2092273103C2777063308 @default.
- W2092273103 hasConceptScore W2092273103C2777472916 @default.
- W2092273103 hasConceptScore W2092273103C2778496288 @default.
- W2092273103 hasConceptScore W2092273103C2778820342 @default.
- W2092273103 hasConceptScore W2092273103C2779490328 @default.
- W2092273103 hasConceptScore W2092273103C2780091579 @default.
- W2092273103 hasConceptScore W2092273103C2780227381 @default.
- W2092273103 hasConceptScore W2092273103C2781068499 @default.
- W2092273103 hasConceptScore W2092273103C29730261 @default.
- W2092273103 hasConceptScore W2092273103C71924100 @default.
- W2092273103 hasConceptScore W2092273103C90924648 @default.
- W2092273103 hasLocation W20922731031 @default.
- W2092273103 hasLocation W20922731032 @default.
- W2092273103 hasOpenAccess W2092273103 @default.
- W2092273103 hasPrimaryLocation W20922731031 @default.
- W2092273103 hasRelatedWork W1967487178 @default.
- W2092273103 hasRelatedWork W2008949143 @default.
- W2092273103 hasRelatedWork W2034058863 @default.
- W2092273103 hasRelatedWork W2099088585 @default.
- W2092273103 hasRelatedWork W2141515963 @default.
- W2092273103 hasRelatedWork W2149456801 @default.
- W2092273103 hasRelatedWork W2149613039 @default.
- W2092273103 hasRelatedWork W2153867442 @default.
- W2092273103 hasRelatedWork W2155319477 @default.
- W2092273103 hasRelatedWork W2156408558 @default.
- W2092273103 hasRelatedWork W2160120519 @default.
- W2092273103 isParatext "false" @default.
- W2092273103 isRetracted "false" @default.
- W2092273103 magId "2092273103" @default.
- W2092273103 workType "article" @default.